Ensysce Biosciences Receives Second Nasdaq Delisting Notice for Equity Deficiency
ENSC sits 31% above its 52-week low of $0.23 on light trading volume (0.1× avg).
Summary
Ensysce Biosciences received a second Nasdaq delisting notice, this time for failing to meet the $2.5 million stockholders' equity requirement, intensifying concerns about its financial viability and continued listing.
Key Events · Corporate Governance and Compliance · ENSC
-
Second Nasdaq Delisting Notice
The company received a notice from Nasdaq on May 21, 2026, for non-compliance with the $2.5 million stockholders' equity requirement (Rule 5550(b)(1)) as of March 31, 2026.
-
Compliance Deadline
Ensysce Biosciences must submit a plan to regain compliance by July 6, 2026. If accepted, an extension of up to 180 days from May 21, 2026, may be granted.
-
Intensified Financial Distress
This notice follows a previous delisting warning for low stock price and recent disclosures of a 'going concern' warning and critical cash shortage, underscoring severe financial challenges.
Analysis · ENSC · Life Sciences
Ensysce Biosciences faces a critical threat to its Nasdaq listing, having received a second delisting notice, this time for failing to meet the $2.5 million stockholders' equity requirement. This follows a previous notice for its stock price falling below $1.00 and recent disclosures of a 'going concern' warning and cash shortage. The company must submit a plan to Nasdaq by July 6, 2026, to avoid delisting, highlighting severe financial distress and increasing the urgency for its announced strategic alternatives review.
At the time of this filing, ENSC was trading at $0.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.7M. The 52-week trading range was $0.23 to $2.75. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.